JP Sheridan, Y. Zhang, K Riester, GN O'Neil, V Vexler and JS Elkins. Change in Circulating Tregs Parallel Reductions in Activated T Cells During Daclizumab Treatment of MS. AAN 2010 poster presentation. 

 JP Sheridan, Y. Zhang, K Riester, GN O'Neil, MT Tang and JS Elkins. Prediction and Characterization of CD56^bright NK Cell Expansion During Daclizumab Treatment for Multiple Sclerosis. AAN 2010 poster presentation.

JP Sheridan, JS Elkins, Y. Zhang, K Riester, GN O'Neill, P Lambert, A Fong, MT Tang and V Vexler. Expansion of CD56^bright NK Cells Correlates with Therapeutic Response to Daclizumab in Multiple Sclerosis. ECTRIMS 2009 poster presentation.

J. P. Sheridan, Y. Zhang, V. Vexler, C. H. Wang, R. Singer, K Riester, Jacob S. Elkins, Alice Fong, and Meina T. Tang. Daclizumab Treatment Reduces Activated T Cells: Results from the CHOICE Multiple Sclerosis Study. AAN 2009 poster presentation.

Bielekova B, Howard T, Packer AN, et al. Effect of Anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch neurol. 2009;66(4):483-489.

L. Neyer, R.Singer,C. H. Wang, andI. Caras. Daclizumab Exhibits Efficacy in Multiple Sclerosis Subjects Positive for Interferon-beta Neutralizing Antibodies. ECTRIMS 2008 poster presentation.

M. T. Tang, C. H. Wang, J. P. Sheridan, L. Neyer, and A. Fong. Exposure-Response Relationship of Daclizumab Added to IFN-beta for Treatment of Multiple Sclerosis during a Phase 2 Study. ECTRIMS 2008 poster presentation. 

M. Kaufman, D.Wynn, X. Montalban. Contemporary Clinica Issues and Case Studies, Plenary Session. Daclizumab in Patients with Active Relapsing Multiple Sclerosis on Concurrent Interferon-beta Therapy Week 44 Data Phase II (CHOICE) Study. AAN 2008 Oral presentation.

X. Montalban, D. Wynn, M. Kaufman. Daclizumab in Patients with Active, Relapsing Multiple Sclerosis on Concurrent Interferon-beta Therapy Week 24 Data-Phase II (CHOICE). ECTRIMS 2007, oral presentation.

Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis. Neurology. 2007;69:785-789.

Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol. 2007. [NEED TO GET FULL REFERENCE]

The International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357.

JW Rose, JB Burns, J Bjorklund, J Klein, H Watt, NG Carlson. Daclizumab Phase I/II Trial in Relapsing and Remitting MS: MRI and Clinical Results, ECTRIMS 2006,  poster presentation.

Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. PNAS. 2006;103(15):5941-5946.

Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. PNAS. 2004;101(23):8705-8708.

F Vincenti, R Kirkman, S Light, G Bumgardner, M Pescovitz, P Halloran, J Neylan, A Wilkinson, H Ekberg, R Gaston, L Backman, J Burdick. (1998). Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation. N Engl J Med. 338: 161-165.

J Hakimi, D Mould , TA Waldmann, C Queen, C Anasetti, S Light. (1997). Development of Zenapax (R): A humanized anti-Tac antibody. Antibody Therapeutics, WJ Harris and JR Adair, Eds. (CRC Press), pp. 277-300.

Tsurushita N, Hinton PR, Kumar S. (2005).  Design of humanized antibodies: From anti-Tac to Zenapax.  Methods 36(1): 69-83.